Predicting Durable Response or Resistance to Antitumor Necrosis Factor Therapy in Inflammatory Bowel Disease

Overview

Journal Therap Adv Gastroenterol

Publisher Sage Publications

Specialty Gastroenterology

Date 2016 Jul 2

PMID 27366220

Citations 34

Authors

Uri Kopylov

Ernest Seidman

Affiliations

Soon will be listed here.

Abstract

Monoclonal antibodies to tumor necrosis factor (TNF) have become a mainstay of the therapeutic armamentarium in inflammatory bowel disease (IBD) over the last 15 years. Although highly effective, primary and secondary nonresponse are common and associated with poor clinical outcomes and significant costs. Multiple clinical, genetic and immunopharmacological factors may impact the response to anti-TNFs. Early stratification of IBD patients by the expected risk of therapeutic failure during the induction and maintenance phases of treatment may allow for treatment optimization and potentially optimal short- and long-term outcomes. The aim of this review is to summarize the current data concerning the potential predictors of therapeutic success and failure of anti-TNFs in IBD.

Citing Articles

Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.

Ballesta-Lopez O, Gil-Candel M, Centelles-Oria M, Megias-Vericat J, Solana-Altabella A, Ribes-Artero H Int J Mol Sci. 2025; 26(4).

PMID: 40004223 PMC: 11855474. DOI: 10.3390/ijms26041760.

High-Throughput Whole-Exome Sequencing and Large-Scale Computational Analysis to Identify the Genetic Biomarkers to Predict the Vedolizumab Response Status in Inflammatory Bowel Disease Patients from Saudi Arabia.

Aljohani H, Anbarserry D, Mosli M, Ujaimi A, Bakhshwin D, Elango R Biomedicines. 2025; 13(2).

PMID: 40002872 PMC: 11852680. DOI: 10.3390/biomedicines13020459.

Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions.

Little R, Jayawardana T, Koentgen S, Zhang F, Connor S, Boussioutas A eGastroenterology. 2025; 2(1):e100006.

PMID: 39944752 PMC: 11770437. DOI: 10.1136/egastro-2023-100006.

Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF-α and IL-23p19 bioactivities.

Wang J, Kang G, Lu H, de Marco A, Yuan H, Feng Z Clin Transl Med. 2024; 14(3):e1636.

PMID: 38533646 PMC: 10966562. DOI: 10.1002/ctm2.1636.

Predictive biomarkers for anti-TNF alpha therapy in IBD patients.

Kumar M, Murugesan S, Ibrahim N, Elawad M, Al Khodor S J Transl Med. 2024; 22(1):284.

PMID: 38493113 PMC: 10943853. DOI: 10.1186/s12967-024-05058-1.

References

Narula N, Fedorak R . Does smoking reduce infliximab's effectiveness against Crohn's disease?. Can J Gastroenterol. 2009; 23(2):121-5. PMC: 2694592. DOI: 10.1155/2009/431349. View

Ding N, Hart A, De Cruz P . Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. Aliment Pharmacol Ther. 2015; 43(1):30-51. DOI: 10.1111/apt.13445. View

Wang S, Ohrmund L, Hauenstein S, Salbato J, Reddy R, Monk P . Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum. J Immunol Methods. 2012; 382(1-2):177-88. DOI: 10.1016/j.jim.2012.06.002. View

Ungar B, Haj-Natour O, Kopylov U, Yavzori M, Fudim E, Picard O . Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure. Medicine (Baltimore). 2015; 94(18):e673. PMC: 4602524. DOI: 10.1097/MD.0000000000000673. View

Moran G, Dubeau M, Kaplan G, Yang H, Seow C, Fedorak R . Phenotypic features of Crohn's disease associated with failure of medical treatment. Clin Gastroenterol Hepatol. 2013; 12(3):434-42.e1. DOI: 10.1016/j.cgh.2013.08.026. View

Yamada A, Sono K, Hosoe N, Takada N, Suzuki Y . Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Inflamm Bowel Dis. 2010; 16(11):1898-904. DOI: 10.1002/ibd.21259. View

Fasanmade A, Adedokun O, Blank M, Zhou H, Davis H . Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011; 33(7):946-64. DOI: 10.1016/j.clinthera.2011.06.002. View

Billiet T, Vande Casteele N, Van Stappen T, Princen F, Singh S, Gils A . Immunogenicity to infliximab is associated with HLA-DRB1. Gut. 2015; 64(8):1344-5. DOI: 10.1136/gutjnl-2015-309698. View

Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J . Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007; 132(3):863-73. DOI: 10.1053/j.gastro.2006.12.003. View

10.

Scoglio D, Ali U, Fichera A . Surgical treatment of ulcerative colitis: ileorectal vs ileal pouch-anal anastomosis. World J Gastroenterol. 2014; 20(37):13211-8. PMC: 4188879. DOI: 10.3748/wjg.v20.i37.13211. View

11.

Jurgens M, Mahachie John J, Cleynen I, Schnitzler F, Fidder H, van Moerkercke W . Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011; 9(5):421-7.e1. DOI: 10.1016/j.cgh.2011.02.008. View

12.

Harper J, Sinanan M, Zisman T . Increased body mass index is associated with earlier time to loss of response to infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013; 19(10):2118-24. DOI: 10.1097/MIB.0b013e31829cf401. View

13.

Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D . Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362(15):1383-95. DOI: 10.1056/NEJMoa0904492. View

14.

Cosnes J, Gower-Rousseau C, Seksik P, Cortot A . Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011; 140(6):1785-94. DOI: 10.1053/j.gastro.2011.01.055. View

15.

Magro F, Rodrigues-Pinto E, Santos-Antunes J, Vilas-Boas F, Lopes S, Nunes A . High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment. J Crohns Colitis. 2013; 8(2):129-36. DOI: 10.1016/j.crohns.2013.07.005. View

16.

Arnott I, McNeill G, Satsangi J . An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther. 2003; 17(12):1451-7. DOI: 10.1046/j.1365-2036.2003.01574.x. View

17.

Orlando A, Colombo E, Kohn A, Biancone L, Rizzello F, Viscido A . Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis. 2005; 37(8):577-83. DOI: 10.1016/j.dld.2005.01.019. View

18.

Ben-Horin S, Kopylov U, Chowers Y . Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2013; 13(1):24-30. DOI: 10.1016/j.autrev.2013.06.002. View

19.

Seow C, Newman A, Irwin S, Steinhart A, Silverberg M, Greenberg G . Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2009; 59(1):49-54. DOI: 10.1136/gut.2009.183095. View

20.

Schreiber S, Khaliq-Kareemi M, Lawrance I, Thomsen O, Hanauer S, McColm J . Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357(3):239-50. DOI: 10.1056/NEJMoa062897. View